Sagimet Biosciences (NASDAQ:SGMT) and Dianthus Therapeutics (NASDAQ:DNTH) Financial Analysis

Dianthus Therapeutics (NASDAQ:DNTH) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Valuation and Earnings

This table compares Dianthus Therapeutics and Sagimet Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04 million	2,823.04	-$162.34 million	($4.15)	-25.38
Sagimet Biosciences	$2.00 million	325.25	-$51.04 million	($1.28)	-8.18

Sagimet Biosciences has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Dianthus Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Dianthus Therapeutics and Sagimet Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1	0	13	1	2.93
Sagimet Biosciences	1	1	9	0	2.73

Dianthus Therapeutics currently has a consensus target price of $129.83, indicating a potential upside of 23.25%. Sagimet Biosciences has a consensus target price of $27.96, indicating a potential upside of 167.16%. Given Sagimet Biosciences’ higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Dianthus Therapeutics.

Insider & Institutional Ownership

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dianthus Therapeutics and Sagimet Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Summary

Sagimet Biosciences beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.